



Approaches to Navigating Multi-Drug Resistance in Gram-Negative Pathogens

Guest Editors:

Dr. Jacinda C. Abdul-Mutakabbir

1. Department of Pharmacy Practice, School of Pharmacy, Loma Linda University, Loma Linda, CA, USA

2. Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, USA

Prof. Dr. Victor Nizet

Division of Host-Microbe Systems and Therapeutics, University of California-San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA

Deadline for manuscript submissions:

31 July 2024

Message from the Guest Editors

Dear Colleagues,

Acinetobacter baumannii is a ubiquitous Gram-negative bacterium and human colonizer. The organism has emerged as a problematic nosocomial pathogen due to its resilience within the hospital environment and innate ability to evade commonly used antibiotic therapy. This Special Issue welcomes various submission types, such as perspectives, reviews, case reports, brief reports, and original research papers that discuss antibiotic treatment for *A. baumannii* infections, with a special focus on multidrug resistance.

Keywords: multidrug-resistant pathogens; pharmacokinetics; pharmacodynamics; antibacterial; *Acinetobacter baumannii*; difficult to treat pathogens; carbapenem-resistant *Acinetobacter baumannii*





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)